China's Active Pharmaceutical Ingredients Industry Analysis - The Thriving World of Active Pharmaceutical Ingredients: Exploring the Dynamic Landscape

The global bulk active pharmaceutical ingredients (API) market experienced a decline in 2020 due to the impact of the COVID-19 pandemic, with the market size dropping from $182.2 billion in 2019 to $175.0 billion, reflecting a decrease of 3.95%. However, the market swiftly rebounded and resumed its growth trajectory starting from 2021, reaching a market size of $204.0 billion in 2022.

In China, the production capacity of bulk API demonstrated an overall growth trend between 2013 and 2017. However, from 2018 to 2019, the sector faced challenges due to stricter environmental and safety regulations, as well as ongoing supply-side reforms. This led to the elimination of outdated, high-energy-consuming, high-pollution, and surplus API production capacity, resulting in a noticeable decline in China's API capacity. The Chinese API market began its recovery in 2020, albeit with a slow growth rate of approximately 4.2% influenced by the pandemic. However, starting from 2021, the growth rate accelerated, reaching around 13.2% compared to 2020. By 2022, China's API capacity exceeded its highest capacity in 2017, with a growth rate of approximately 17.5% compared to 2021.

Despite the temporary setback caused by the pandemic, both the global and Chinese bulk API markets have demonstrated resilience and a strong rebound in recent years. This article will delve deeper into the current landscape of the global and Chinese bulk API markets, highlighting key trends, factors driving growth, and the role of major players in these markets.

1. The Era of Bulk APIs: Unveiling the Powerhouses
As the backbone of the pharmaceutical industry, bulk APIs encompass essential compounds that form the basis of numerous drugs. We take a closer look at the mature market of bulk APIs, dominated by China, and examine the key categories such as vitamins, antibiotics, antipyretic and analgesic drugs, and corticosteroids. With China's stronghold in production, we explore the challenges and opportunities faced by the multitude of participants in the domestic and global market.

Zhejiang NHU Co. Ltd.:
Established in 1999 and listed on the stock market in 2004 (stock code: 002001), NHU is committed to innovation-driven development and growth in the market competition. The company specializes in research, production, sales, and services related to functional chemicals such as nutritional supplements, flavors, and polymeric materials. NHU provides comprehensive solutions in the fields of nutrition and health, personal care, transportation, environmental protection, energy, and more, catering to customers from over 100 countries and regions worldwide.

Zhejiang Garden Biopharmaceutical Co Ltd:
Garden Biopharmaceutical (stock code: 300401) primarily focuses on the research, production, and sales of a range of upstream and downstream products related to Vitamin D3. Their main products include lanolin cholesterol, Vitamin D3, 25-hydroxy Vitamin D3, and others. Recognized as a national high-tech enterprise, Garden Biopharmaceutical is involved in national high-tech industrialization demonstration projects and national comprehensive utilization of resources projects.

Zhejiang Medicine Co., Ltd.:
Zhejiang Medicine is a company primarily engaged in pharmaceutical manufacturing. Established in 1954 and headquartered in Hangzhou, Zhejiang Province, the company boasts top-tier facilities for chemical pharmaceuticals, microbial pharmaceuticals, and formulations production. It is also involved in the production of natural drugs, food additives, and feed additives. Zhejiang Medicine serves as a significant production base for vitamins, antibiotics, and fluoroquinolone drugs in China. The company has been recognized as a national high-tech enterprise, a national enterprise technology center, and a national innovative demonstration enterprise. Its core business encompasses pharmaceutical manufacturing, research, and sales, offering a wide range of products, including prescription drugs, over-the-counter drugs, and medical devices. Zhejiang Medicine's product portfolio spans multiple therapeutic areas, including cardiovascular, digestive, respiratory, and nervous systems, among others.

2. Specialty APIs: Unleashing the Potential
The demand for specialty APIs is on the rise, driven by the accelerated growth of downstream formulations and their lifecycles. We shed light on the Chinese market's major players in specialty APIs, including prominent companies like Nanjing Kingfriend Pharma, Shenzhen Hepalink Pharmaceutical Co., Ltd., Zhejiang Huahai, and Zhejiang Tianyu. Additionally, we explore notable categories such as sartans, prils, statins, heparins, and contrast media, and discuss the evolving landscape as research and development techniques advance.

Nanjing Kingfriend Pharma (Stock Code: 603707) is a company focused on the field of biopharmaceuticals. Established in 2000, it was formerly known as Nanjing Second Biochemical Pharmaceutical Factory. Nanjing Kingfriend Pharma is one of the early pharmaceutical companies in China engaged in heparin extraction, purification, and the development of structural confirmation methods for heparin-like polysaccharide products. The company is currently one of the world's largest manufacturers of heparin active pharmaceutical ingredients (APIs). Nanjing Kingfriend Pharma is primarily engaged in the research, production, and sales of heparin and related products, including heparin sodium, low molecular weight heparin, heparin calcium, and heparin lithium. Its products are widely used in the fields of cardiovascular and cerebrovascular diseases, oncology, orthopedics, gynecology, and obstetrics.

Shenzhen Hepalink Pharmaceutical Co., Ltd. is a multinational pharmaceutical company headquartered in Shenzhen, established in 1998. The company operates an A+H dual-listed financing platform and its main business covers the entire heparin industry chain, biologics contract development and manufacturing organization (CDMO), as well as investment, development, and commercialization of innovative drugs. Hepalink Pharmaceutical is driven by unmet clinical needs and is committed to providing high-quality, safe, and effective drugs and services to patients worldwide, safeguarding health. It holds a leading position in various segments of the heparin industry chain, and its subsidiary, Saibo Biotech, has strong technological capabilities and successful delivery capabilities in the CDMO field. Hepalink Pharmaceutical has 41 subsidiaries worldwide, with operations in China, the United States, Poland, Italy, the United Kingdom, Germany, Spain, and other countries. The company's development journey includes multiple acquisitions and integrations, such as the acquisition of SPL in the United States and Saibo Biotech, consolidating its position in the heparin sodium API market and venturing into the CDMO business. Hepalink Pharmaceutical values innovation, integrity, responsibility, and win-win cooperation, and is committed to contributing to human health.

Zhejiang Huahai, founded in 1989 as the Linhai Xunqiao Synthetic Chemical Factory, was transformed into Zhejiang Huahai Pharmaceutical Co., Ltd. in January 2001. In March 2003, the company's stock was successfully listed on the Shanghai Stock Exchange. Zhejiang Huahai Pharmaceutical Co., Ltd. is a national high-tech enterprise, an innovative enterprise recognized by the national government, and one of the "Five-Batch" key enterprises confirmed by the provincial government. It has a national enterprise technology center and postdoctoral research workstations. It is the first pharmaceutical company in China to be awarded the title of "National Environmentally Friendly Enterprise." From 2000 to 2008, it ranked among the top ten pharmaceutical companies in Zhejiang Province for nine consecutive years. In 2019, it ranked 84th on the list of the top 100 Zhejiang high-tech enterprises. On March 18, 2020, Huahai Pharmaceutical ranked 52nd on the "2020 Hurun China Top 100 Private Enterprises in the Healthcare Industry" with a market value of 28 billion RMB. The company's main business includes pharmaceutical formulations, APIs, and intermediates. It has formed a distinct product portfolio with a focus on cardiovascular drugs, antidepressants, and antiviral drugs, characterized by precision, refinement, and large-scale development. Among them, the ACE inhibitor products in the cardiovascular drug category have the largest number of varieties and sales volume, leading in technology, and enjoying the reputation of "Lisinopril Expert." The company has sound management systems, and all its products have passed the national Good Manufacturing Practice (GMP) certification. It is one of the domestic enterprises with the most international drug quality certifications.

Zhejiang Tianyu is a pharmaceutical company specializing in the research, manufacturing, and sales of advanced pharmaceutical intermediates, specialty APIs, and formulations. Founded in 2003, it is headquartered in Taizhou, Zhejiang, and has research and development centers or production bases in Shanghai, Yancheng, Weifang, Changzhou, and other locations. The company's main products cover intermediate, API, and formulation categories of antihypertensive, antidiabetic, lipid-lowering, antithrombotic, and anti-asthma drugs. It is one of the major global manufacturers of cardiovascular APIs, and its products are well-received in both domestic and international markets.

3. Custom APIs: A Niche Market with Boundless Opportunities
In this section, we uncover the realm of custom APIs, catering to the specific needs of innovative pharmaceutical companies. With a higher barrier to entry due to demanding research and development requirements, this sector offers tremendous growth potential. We highlight reputable enterprises like ASYMCHEM, Zhejiang Ausun, Porton Pharma Solutions, and STA Pharma, and emphasize the flexibility and adaptability of custom APIs to meet the diverse demands of the pharmaceutical industry.

ASYMCHEM: ASYMCHEM is a pharmaceutical company headquartered in Shanghai, China. The company specializes in the research, development, production, and sale of innovative drugs, with a focus on providing innovative drug solutions for the treatment of cancer and other serious diseases. ASYMCHEM has extensive research and clinical experience in the field of oncology and is dedicated to developing highly effective and safe anticancer drugs. The company's research projects cover various therapeutic areas, including lung cancer, breast cancer, gastric cancer, colorectal cancer, etc.

Zhejiang Ausun: Zhejiang Ausun (603229) is a publicly listed pharmaceutical company based in Shanghai, China. The company is dedicated to the research, development, production, and sale of innovative drugs, particularly in the field of oncology where it has extensive research and clinical experience. Zhejiang Ausun aims to provide drug solutions for the treatment of cancer and other serious diseases. By developing and producing innovative drugs, the company strives to offer better treatment options, improve patients' quality of life, and contribute to the global healthcare industry. Zhejiang Ausun focuses on innovation and technological advancements, continuously strengthening its research and development capabilities, and collaborating with domestic and international research institutions and pharmaceutical companies to drive drug development and innovation.

Porton Pharma Solutions: Porton Pharma Solutions is a pharmaceutical technology company founded in 2005 and headquartered in Chongqing, China. The company provides customized research and production services for the entire life cycle of pharmaceuticals, from preclinical research to commercialization, including small-molecule drugs, peptides, oligonucleotides, biologics, gene and cell therapies, and other areas. Porton Pharma Solutions has research, production, and operation facilities worldwide, including locations in China (Chongqing, Shanghai, Sichuan, Jiangsu, Jiangxi, Hubei, Hong Kong), the United States, Slovenia, Belgium, Switzerland, and Denmark, with over 5,000 employees. The company went public in 2014 and became the first CMO-focused company in China to be listed on the A-share market. By leveraging the capital market, Porton Pharma Solutions has expanded both horizontally and vertically along the industry chain. During its transformation from CMO to CDMO, the company has shifted from providing customized research and production outsourcing services to offering comprehensive research and production capabilities. To enhance its independent research and development capabilities, Porton Pharma Solutions has invested over 1.1 billion yuan in research and development, establishing eight R&D centers covering the CDMO segments of API, formulation, and gene and cell therapy. The company has achieved significant growth in its performance, with total revenue reaching 7.035 billion yuan in 2022, a year-on-year increase of approximately 127%, and a net profit attributable to shareholders of 2.005 billion yuan, a year-on-year increase of approximately 283%. Porton Pharma Solutions is now among the top three CDMO platforms in China and a leader in the global market.

STA Pharma: STA Pharma is an integrated pharmaceutical company that provides research, development, production, analysis, and new drug application support services for both active pharmaceutical ingredients (APIs) and formulation processes, covering the entire journey from preclinical research to commercialization. The company's Clinical Supply Services (CSS) supports the rapid delivery of Clinical Trial Materials (CTMs) to clinical trial centers by integrating with upstream API and formulation production, empowering the "last mile" of clinical supply.

The world of active pharmaceutical ingredients is a dynamic and multifaceted landscape. From the established market of bulk APIs to the burgeoning specialty APIs and the niche domain of custom APIs, each category presents its own challenges and opportunities. As the industry continues to evolve, innovation, research, and collaboration will be instrumental in driving forward the development of life-saving drugs and therapies. By understanding the distinct characteristics of each API category, we can navigate this intricate ecosystem and contribute to the advancement of global healthcare.